-
Innovation Ranking
NewInnovation Ranking – Aeterna Zentaris Inc
Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of unmet medical needs. The company’s lead product, Macrilen (macimorelin), a ghrelin receptor agonist and the orally active small molecule is used for the treatment of patients with adult growth hormone deficiency (AGHD). The company has operations in the US, Canada, and Germany and has license agreements for its products in Ireland, China, the British Virgin...
-
Product Insights
Neuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Drugs In Development, 2023’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Cancer Anorexia-Cachexia Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Cancer Anorexia-Cachexia Syndrome - Drugs In Development, 2023’, provides an overview of the Cancer Anorexia-Cachexia Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hypoparathyroidism – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypoparathyroidism - Drugs In Development, 2023’, provides an overview of the Hypoparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypoparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Growth Hormone Deficiency – Drugs In Development, 2023
Global Markets Direct’s, ‘Growth Hormone Deficiency - Drugs In Development, 2023’, provides an overview of the Growth Hormone Deficiency pipeline landscape. The report provides comprehensive information on the therapeutics under development for Growth Hormone Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARO-MUC5AC in Chronic Obstructive Pulmonary Disease (COPD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARO-MUC5AC in Chronic Obstructive Pulmonary Disease (COPD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARO-MUC5AC in Chronic Obstructive Pulmonary Disease (COPD) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Macimorelin Acetate in Growth Hormone Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Macimorelin Acetate in Growth Hormone Deficiency report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Macimorelin Acetate in Growth Hormone Deficiency Drug Details: Macimorelin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efatutazone in Myxoid Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efatutazone in Myxoid Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efatutazone in Myxoid Liposarcoma Drug Details: Efatutazone (CS-7017) is under development...
-
Company Profile
Aeterna Zentaris Inc – Company Profile
Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of unmet medical needs. The company’s lead product, Macrilen (macimorelin), a ghrelin receptor agonist and the orally active small molecule is used for the treatment of patients with adult growth hormone deficiency (AGHD). The company has operations in the US, Canada, and Germany and has license agreements for its products in Ireland, China, the British Virgin...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – macimorelin acetate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry macimorelin acetate Drug Details Macimorelin acetate (AEZS-130) is under development for the treatment cancer-induced...